Prior notification of a concentration (Case M.10469 — GS/Charlesbank/MDVIP) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 365/07
Date: 2021-09-10
Institutions: Directorate-General for Competition, European Commission
Subjects: banking, economic concentration, health care, investment company, merger control








C_2021365EN.01001101.xml










10.9.2021   


EN


Official Journal of the European Union


C 365/11






Prior notification of a concentration
(Case M.10469 — GS/Charlesbank/MDVIP)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 365/07)

1.   
On 2 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Goldman Sachs Group, Inc. (‘GS’, United States),










—


Charlesbank Capital Partners, LLC (‘Charlesbank’, United States),










—


MDVIP, Inc. (‘MDVIP’, United States).




GS and Charlesbank acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of MDVIP.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are:






—


for GS: a global investment banking, securities and investment management firm that provides a range of services worldwide to corporations, financial institutions, governments and high-net-worth individuals. GS’ global activities are generally divided into four segments: (i) global markets/fixed income, currencies, and commodities, (ii) investment banking, (iii) asset management, and (iv) consumer and wealth management,










—


for Charlesbank: a private equity firm with portfolio companies active in business services, consumer, healthcare, industrial, technology and technology infrastructure, primarily in North America,










—


for MDVIP: operation of a network of physicians in the US who provide membership based primary care services to patients, focusing on delivering personalised medicine, patient-centered and preventive care.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10469 — GS/Charlesbank/MDVIP
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.